Abstract: A bispecific antibody, including: a first antibody or antigen-binding fragment thereof that specifically binds to a first antigen; and a second antibody or antigen-binding fragment thereof that specifically binds to a second antigen; where the first antigen is a tumor-associated antigen (TAA), and the second antigen is TNFR2. The bispecific antibody can target a tumor-associated antigen (TAA), and at the same time can stimulate the proliferation of CD8+ T cells, activate CD8+ T cells, and release anti-tumor factors such as IFN? and IL2 by using a TNFR2 agonistic antibody; or can block TNF-TNFR2 and inhibit the proliferation of Treg by using a TNFR2 antagonistic antibody.

Abstract: A bispecific antibody, including: (a) a first antibody or antigen-binding fragment thereof that specifically binds to a first antigen; and (b) a second antibody or antigen-binding fragment thereof that specifically binds to a second antigen; where the first antigen is a T cell immunomodulator, and the second antigen is TNFR2. The bispecific antibody is a T cell regulator of tumor microenvironment, which can stimulate the proliferation of CD8+T cells, activate CD8+T cells, and release anti-tumor factors, such as IFN? and IL2 by using a TNFR2 agonistic antibody; or can block TNF-TNFR2 and inhibit the proliferation of Treg by using a TNFR2 antagonistic antibody. At the same time, it can further relieve immunosuppression, increase the number of anti-tumor cells and solve the limitation of heterogeneity of TME by cooperating with T cell immunomodulator at the target or systemic system.

Abstract: A bispecific antibody, including: a first antibody or antigen-binding fragment thereof that specifically binds to a first antigen; a second antibody or antigen-binding fragment thereof that specifically binds to a second antigen; where the first antigen is TNFR2, and the second antigen is 4-1BB; or, the first antigen is 4-1BB, and the second antigen is TNFR2. The bispecific antibody is a T cell regulator of the tumor microenvironment, which can stimulate the proliferation of CD8+T cells, activate CD8+T cells, and release anti-tumor factors, such as IFN? and IL2 by using a TNFR2 agonistic antibody, or can block TNF-TNFR2 and inhibit the proliferation of Treg by using a TNFR2 antagonistic antibody. The bispecific antibody can simultaneously target 4-1BB, activate the 4-1BB signaling pathway of T cells and NK cells, enhance the killing power of cytotoxic T cells and NK cells, and produce anti-tumor activity.

Abstract: A multifunctional antibody acquired via a genetic engineering technique, targeting PD-1 and, at the same time, providing biological effects of an IL-15/IL-15R? complex, a nucleic acid molecule encoding the antibody, a recombinant vector comprising the nucleic acid molecule, a recombinant cell comprising the recombinant vector, a preparation method for the multifunctional antibody, and medicinal uses thereof. The multifunctional antibody effectively solves drug resistance against a single target antibody medicament and relapse, also reduces the effective dose, kills tumor cells more effectively, and extends the survival period of in situ tumor model animals; and, compared with an IL-15 or IL-15/IL-15 receptor complex, extends the serum half-life, increases tumor targeting, and reduces toxic and side effects.

Abstract: Provided is an anti-ILT4 single-domain antibody and antigen-binding fragment thereof. Also provided are a method of using it for the treatment or prevention of a disease in a subject, and a method of preparing the antibody and antigen-binding fragment thereof.

Abstract: A heterodimeric fusion protein and use thereof. The heterodimeric fusion protein includes: a first heavy chain, wherein the first heavy chain includes an Fc region, an immunomodulator fused to the Fc region; a light chain and a second heavy chain, wherein the light chain and the second heavy chain are complexed to form a targeting portion exhibiting binding specificity to a tumor antigen or an immune checkpoint; and the light chain, the first heavy chain, and the second heavy chain are complexed to form a heterodimeric fusion protein, wherein the immunomodulator in the first heavy chain may contain a mutation. The heterodimeric fusion protein has high affinity for both tumor-associated targeting antigens and IL-10 receptors and has good anti-tumor activity.

Abstract: A bispecific antigen binding protein, including (a) a first antibody or antigen binding fragment thereof that specifically binds to a first antigen; and (b) a second antibody or antigen binding fragment thereof that specifically binds to a second antigen. In the embodiments, the first antigen is CD24, and the second antigen is 4-1BB; or, the first antigen is 4-1BB, and the second antigen is CD24.

Abstract: An antibody or antigen-binding fragment thereof that binds specifically to TNFR2 with high affinity. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, an expression vector and a host cell for expressing the antibody or antigen-binding fragment thereof, and a method for producing the antibody or antigen-binding fragment thereof are also provided. Also included are an antibody-drug conjugate and a drug composition including the antibody or antigen-binding fragment thereof, and a combination therapy with other therapeutic agents, as well as the preparation of a drug for the treatment of a variety of diseases using the antibody or antigen-binding fragment thereof.

Abstract: An anti-CD24 antibody or antigen-binding fragment thereof capable of binding to CD24, and/or capable of exerting an anti-tumor effect through an antibody Fc fragment, and use thereof.

Abstract: An antibody against CEACAM5 and CEACAM6 or antigen-binding fragment thereof, and the use thereof. The antibody is an antibody against CEACAM5 and CEACAM6, which antibody has a good performance, and can specifically bind to both targets CEACAM5 and CEACAM6 with a high affinity, thereby expanding antibody indications. The antibody against CEACAM5 and CEACAM6 has a binding specificity, hardly binds to normal cells, and only binds to overexpressed tumor cells, thereby reducing adverse effects caused by non-specific binding. The antibody also has a good endocytosis activity, and can be used for coupling a cytotoxic drug to form an antibody-drug conjugate for anti-tumor therapy.

Abstract: An anti-CCR8 antibody or antigen-binding fragment thereof. The anti-CCR8 antibody can recognize human CCR8 protein, block the signal pathway between CCR8 and CCL1/CCL18, and recognize cells expressing CCR8, and also has target specific ADCC activity on target cells expressing CCR8.

Abstract: In the technical field of biomedicine, a bispecific antibody including (a) a first antibody that specifically binds to a first antigen or antigen binding fragment thereof; and (b) a second antibody that specifically binds to a second antigen or antigen binding fragment thereof. Specifically, the first antigen is B7H3 and the second antigen is NKP30, or the first antigen is NKP30 and the second antigen is B7H3.

Abstract: An anti-human TNFR2 antibody or antigen-binding fragment thereof and uses and pharmaceutical compositions thereof. The anti-human TNFR2 antibody or antigen-binding fragment thereof is capable of specifically binding to TNFR2, inhibiting Treg cell proliferation, and/or promoting effector Teff cell proliferation and activation.

Abstract: In the field of biomedicine, a heterodimeric protein and application thereof. The heterodimeric protein includes: (1) a light chain and a first heavy chain, where the light chain and the first heavy chain are combined to form a targeting moiety that exhibits binding specificity to a tumor antigen or an immune checkpoint, and the tumor antigen or the immune checkpoint includes B7H3; (2) a second heavy chain, wherein the second heavy chain includes a Fc region and an immunomodulator fused to the Fc region, and the immune regulator includes IL-10. The results of affinity test showed that the heterodimeric protein had high affinity for B7H3 and IL-10 receptors. The results of pharmacodynamic experiments in vivo showed that the heterodimeric protein had good anti-tumor activity.

Abstract: A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of recognizing the first antigen, where the first antigen is a tumor-associated antigen (TAA); (b) a second antigen-binding portion, where the second antigen-binding portion is an innate immune cell agonist; and (c) a third antigen-binding portion capable of recognizing the third antigen, where the third antigen regulates the tumor microenvironment. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.

Abstract: A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of recognizing the first antigen, where the first antigen is targeted to antigens associated with tumorigenesis or progression; (b) a second antigen-binding portion, where the second antigen-binding portion is an innate immune cell agonist; and (c) a third antigen-binding portion capable of recognizing the third antigen, where the third antigen regulates tumor microenvironment by regulating normal and abnormal angiogenesis. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.

Abstract: A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of specifically recognizing the first antigen, where the first antigen is a tumor-associated antigen (TAA); (b) a second antigen-binding portion, where the second antigen-binding portion is an NK cell activator; and (c) a third functional portion, where the third functional portion includes a cytokine and/or a cytokine receptor. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.

Abstract: The present invention discloses an anti-NKp30 single domain antibody capable of activating the release of cytokines from NK cells or ??T cells, and a nucleic acid encoding the anti-NKp30 single domain antibody. The present invention also discloses a multifunctional fusion protein comprising the anti-NKp30 single domain antibody and a composition thereof, and the use in drugs for the treatment, prevention or diagnosis of diseases.

Abstract: The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in Formula I, a pharmaceutical composition containing same or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.

Abstract: A multifunctional antibody acquired via a genetic engineering technique, targeting PD-1 and, at the same time, providing biological effects of an IL-15/IL-15R? complex, a nucleic acid molecule encoding the antibody, a recombinant vector comprising the nucleic acid molecule, a recombinant cell comprising the recombinant vector, a preparation method for the multifunctional antibody, and medicinal uses thereof. The multifunctional antibody effectively solves drug resistance against a single target antibody medicament and relapse, also reduces the effective dose, kills tumor cells more effectively, and extends the survival period of in situ tumor model animals; and, compared with an IL-15 or IL-15/IL-15 receptor complex, extends the serum half-life, increases tumor targeting, and reduces toxic and side effects.